|
Jun 26
|
Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study
|
|
Feb 6
|
Crossject provides strategic update on priorities for 2024
|
|
Jan 9
|
Crossject to present at Biotech Showcase on January 9 at 16:30 PT
|
|
Dec 22
|
Crossject signs ZEPIZURE® commercialization agreement for northern Europe
|
|
Nov 28
|
Crossject announces initiation of coverage by ODDO BHF
|
|
Jul 20
|
Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
|